Towards a pan-European consensus on the treatment of patients with colorectal liver metastases

Cutsem, Éric Van; Nordlinger, Bernard; Adam, René; Köhne, Claus‐Henning; Pozzo, Carmelo; Poston, Graeme J.; Ychou, Marc; Rougier, Philippe

doi:10.1016/j.ejca.2006.04.012

Cited by 499 publications

(369 citation statements)

References 69 publications

Supporting

Mentioning

335

Contrasting

Unclassified

Order By: Relevance

“…Data on antibodies were also identified in relevant publications and from listings in recent overviews (Veronese and O'Dwyer, 2004;Nygren et al, 2005;Stern and Herrmann, 2005;Arnold et al, 2006;Saunders and Iveson, 2006;Van Cutsem et al, 2006). Full reporting of final results from important clinical trials often lags behind more preliminary reports in the abstract form.…”

Section: Principles For Retrieval Of Datamentioning

confidence: 99%

Current role of antibody therapy in patients with metastatic colorectal cancer

2007

View full text Add to dashboard Cite

Section: Principles For Retrieval Of Datamentioning

confidence: 99%

Current role of antibody therapy in patients with metastatic colorectal cancer

2007

View full text Add to dashboard Cite

“…Standard combination chemotherapy regimens comprising 5-fluorouracil (5-FU) plus leucovorin [LV] in combination with irinotecan, typically FOLFIRI or oxaliplatin (FOLFOX) have been reported to facilitate the resection of 9-40 % of initially unresectable metastases, and a median survival of 15 to 20 months [7][8][9]. Although, intensified chemotherapy such as FOLFOXIRI (i.e., oxaliplatin, 5-FU/LV and irinotecan) has been shown to have high response and conversion rates (19 %); however, it has not been generally recommended thus far due to its considerable toxicity [10].…”

Section: Introductionmentioning

confidence: 99%

Assessment of Tumor Response and Resection Rates in Unresectable Colorectal Liver Metastases Following Neoadjuvant Chemotherapy with Cetuximab

Somashekhar

Ashwin

Zaveri

et al. 2015

Indian J Surg Oncol

View full text Add to dashboard Cite

To investigate efficacy and safety of cetuximab combined with neo adjuvant chemotherapy regimen in patients with unresectable colorectal liver. This was a prospective trial with rate of Ro liver metastases resection as primary end point. Between January 2010 and December 2014, 46 patients with unresectable liver metastases from colon or rectum were enrolled. Patients received Cetuximab along with neoadjuvant chemotherapy where 34 (74 %) and 12 (26 %) patients received FOLFOX and FOLFIRI, respectively. They were assessed for response after 2-3 cycles by CT scan. Patients with resectable disease were offered liver surgery within 3-6 weeks of the last treatment cycle. The primary end point was resection rate of liver metastases, which was evaluated in all patients. Secondary end points were response rate according to Response evaluation criteria in solid tumors (RECIST) criteria, perioperative morbidity and mortality. An objective response was observed in 28 (60.9 %) patients. Seven (15.2 %) patients were reported radiologically to have a complete response (CR); 21 (45.7 %) patients had radiological partial response (PR). An additional 12 patients (26.1 %) demonstrated stable disease (SD) and only six patients (13.0 %) had disease progression (PD). Microscopically complete resections (R0 resection) was performed in all 28 patients (60.9 %). The most frequent toxicities were skin rash and diarrhoea. There was no operative mortality. Chemotherapy with cetuximab yields high response rates compared with historical controls, and leads to significantly increased resectability. Complete resection of previously unresectable colorectal liver metastases can be performed with minimal morbidity and mortality. This therapeutic strategy involves a multimodal approach.

show abstract

“…Distant metastasis is the main cause of death in CRC patients. The liver is the most frequent (approximately 33%) metastatic site (Van Cutsem et al, 2006;Cui et al, 2013). Colorectal liver metastases (CLM) are present in 15% to 25% of cases at the time of diagnosis of the primary tumor (synchronous metastases), and approximately half of the patients undergoing radical resection of CRC will develop metastatic disease (metachronous metastasis) (Van Cutsem et al, 2006;Dong et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

“…The liver is the most frequent (approximately 33%) metastatic site (Van Cutsem et al, 2006;Cui et al, 2013). Colorectal liver metastases (CLM) are present in 15% to 25% of cases at the time of diagnosis of the primary tumor (synchronous metastases), and approximately half of the patients undergoing radical resection of CRC will develop metastatic disease (metachronous metastasis) (Van Cutsem et al, 2006;Dong et al, 2013). Nearly 50%-60% of patients with colorectal cancer will eventually develop metastatic disease during the course of their disease (Van Cutsem et al, 2006;Hsu et al, 2011;Dong et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

“…Surgical resection remains at the present time the only potentially curative treatment for patients with CLM (Van Cutsem et al, 2006;Dong et al, 2013). Five-year survival after curative resection ranges 30%-40% (up to 60% in selected series), whereas less than 2% of patients are alive 5 years after diagnosis without surgical therapy (Castaing et al, 2009;Hsu et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Survival Outcomes of Liver Metastasectomy in Colorectal Cancer Cases: A Single-Center Analysis in Turkey

Cokmert¹,

Ellıdokuz²,

Demir³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The purpose of this study was to analyze our series of liver resections for metastatic colorectal carcinoma (mCRC) to determine prognostic factors affecting survival and to evaluate the potential roles of neoadjuvant or adjuvant chemotherapy. Materials and Methods: Ninety-nine patients who underwent metastasectomy for liver metastases due to colorectal cancer at the Department of Medical Oncology, 9 Eylul University Hospital between 1996 and 2010 were evaluated in this study. The patients were followed through July 2013. Demographic, perioperative, laboratory, radiological and chemotherapy as well as survival data were obtained by retrospective chart review. Results: In 47 (47.5%) patients, liver metastases were unresectable at initial evaluation; the remaining 52 (52.5%) patients exhibited resectable liver metastases. Simultaneous hepatic resection was applied to 52 (35.4%) patients with synchronous metastasis, whereas 5 (64.5%) patients underwent hepatic resection after neoadjuvant chemotherapy. Forty-two patients with metachronous metastasis underwent hepatic resection following neoadjuvant chemotherapy. R0 resection was obtained in 79 (79.8%) patients. A second hepatectomy was performed in 22 (23.2%) patients. Adjuvant chemotherapy was given to 85 (85.9%) patients after metastasectomy. The median disease-free and overall survivals after initial metastasectomy were 12 and 37 months, respectively, the 1-year, 3-year and 5-year disease-free survival (DFS) and overall survival (OS) rates being 46.5%, 24.3% and 17.9%and 92.3%, 59.0% and 39.0%, respectively. On multivariate analysis, the primary tumor site, tumor differentiation, resection margin and DFS were independent factors predicting better overall survival. Conclusions: In selected cases, hepatic metastasectomy for mCRC to the liver can result in long-term survival. Neoadjuvant chemotherapy did not exert a positive effect on DFS or OS. Adjuvant chemotherapy also did not appear to impact DFS and OS.

show abstract

Towards a pan-European consensus on the treatment of patients with colorectal liver metastases

Cited by 499 publications

References 69 publications

Current role of antibody therapy in patients with metastatic colorectal cancer

Current role of antibody therapy in patients with metastatic colorectal cancer

Assessment of Tumor Response and Resection Rates in Unresectable Colorectal Liver Metastases Following Neoadjuvant Chemotherapy with Cetuximab

Survival Outcomes of Liver Metastasectomy in Colorectal Cancer Cases: A Single-Center Analysis in Turkey

Contact Info

Product

Resources

About